Recurrence Monitoring

"In another study in melanoma, ctDNA detected after surgery identified patients at highest risk of recurrence, and its continued presence during follow-up treatment signaled early relapse and poor survival despite standard therapy (1089)Syeda MM, et al. (2025) Lancet Oncol, 26: 641.. In cervical cancer, results from a phase III clinical trial showed that detection of ctDNA after treatment predicted relapse and survival. Personalized ctDNA tests could detect signs of cancer recurrence months before it appeared on scans, while patients with detectable ctDNA after treatment were significantly more likely to experience relapse (1090)Mayadev J, et al. (2025) Ann Oncol.. These studies demonstrate how liquid biopsy approaches are helping clinicians personalize posttreatment care, offering a less invasive, highly sensitive tool to detect recurrence and plan clinical care."